A practical reference on synthetic peptide: what it is, how it behaves, what the literature reports, and where the honest uncertainties sit.
Reviewed 2026-03-02. Anything still debated is marked as such rather than presented as settled.
The peptide is frequently described as a growth hormone fragment, although it is chemically distinct from full-length hGH. AOD-9604 contains 16 amino acids and includes two cysteine residues that can form an intramolecular disulfide bond. In solution, this structural feature can influence folding, aggregation, and stability. Published descriptions sometimes call it hGH 176-191 or AOD9604, with spacing and capitalization varying. Such naming differences can complicate literature searches, database entries, and product verification.
Researchers have studied the fragment in cell and animal models to understand its metabolic actions. Some experiments report effects on fat breakdown and fat storage pathways, but the underlying mechanism remains incompletely defined. AOD-9604 does not appear to stimulate the same broad growth hormone receptor signaling as full-length hGH. Whether its observed activities arise from direct receptor interactions or downstream metabolic changes is an open question. Results from different assays are not always consistent.
Regulatory interest in AOD-9604 increased after high-profile anti-doping cases involving peptide products. In some cases, the substance was supplied under alternative names or in compounded preparations, complicating traceability. Sports tribunals and anti-doping panels have discussed whether the peptide was explicitly banned at the time of use, leading to clarifications by the World Anti-Doping Agency. For consumers and researchers, the legal status can vary by jurisdiction, and products marketed as research chemicals may lack independent quality verification.
AOD-9604 is listed as a prohibited substance in sport by the World Anti-Doping Agency. It falls under the peptide hormones, growth factors, related substances, and mimetics class on the prohibited list. Anti-doping organizations treat its presence in an athlete's sample as an adverse finding unless a therapeutic use exemption applies. The prohibition reflects concerns about performance enhancement in competitive settings and the difficulty of distinguishing exogenous peptide use from endogenous hormone fragments.
| Property | Value | Notes |
|---|---|---|
| Molecular class | Synthetic peptide | Derived from a fragment of human growth hormone |
| Sequence basis | hGH residues 176-191 | Commonly described as a 16-amino-acid fragment |
| Appearance | White to off-white powder | Typical for lyophilized research peptides |
| Solubility | Soluble in water or aqueous buffer | Exact solubility depends on pH and purity |
| Common synonyms | AOD9604; hGH 176-191 | Spelling and punctuation vary across sources |
Regulatory status varies by country. In the United States, AOD-9604 is not approved as a prescription drug. It is sometimes sold as a research chemical or dietary supplement, though such marketing may fall outside legal frameworks. The World Anti-Doping Agency prohibits its use in sport. Researchers must obtain it through legitimate suppliers and follow institutional rules. Its legal classification continues to evolve as authorities increasingly assess peptide products more broadly.
AOD-9604 is a synthetic peptide whose sequence matches the C-terminal fragment of human growth hormone, specifically residues 176 through 191. This region differs from the full hormone in its receptor interactions. The peptide is not a growth hormone secretagogue and does not bind the growth hormone receptor in the same manner. Researchers have examined it for effects on lipid metabolism, but its exact pharmacological profile remains an active area of study.
Research interest in AOD-9604 often focuses on whether it can influence lipid metabolism without the growth-promoting or glucose-related effects of full-length hGH. This question remains unresolved, and findings depend on model, dose, and measurement method. Some reviews treat the peptide as a historical obesity candidate rather than an active therapeutic. Others cite it in discussions of peptide fragments, metabolic signaling, and performance-enhancing substances. Clear conclusions are limited by the small number of rigorous, independent human studies.
AOD-9604 has been investigated primarily as a potential treatment for obesity and related metabolic conditions. Early laboratory work examined its effects on fat cells, and later studies moved into animal models and human clinical trials. Some trials reportedly reached Phase II, but the program did not lead to an approved medicine. Published summaries often note that weight-loss results were modest or inconsistent. The full trial data are not all publicly available in detail.
Regulatory treatment of AOD-9604 has varied. In sports anti-doping, the peptide became widely discussed during a 2013 investigation into an Australian professional sports club. Authorities at the time debated whether it fell under prohibitions on growth hormone and related substances. Later clarifications and updated lists have addressed the compound in different ways. Anyone seeking current status should consult the latest applicable rules, and commercial supply for human use is not authorized in major markets.
Early interest in AOD-9604 centered on whether a fragment of human growth hormone could influence fat metabolism without the broader effects of the full hormone. Cell and animal studies reported changes in fat storage and breakdown. Human trials followed, but the results were not strong enough to secure regulatory approval. The compound remains available for laboratory research, and its clinical potential is still described as uncertain. Studies continue to examine its activity and safety profile.
AOD-9604 is a synthetic peptide that corresponds to a short section of human growth hormone. It is commonly identified as hGH fragment 176-191 because its sequence matches residues at the C-terminal end of the hormone. The molecule contains sixteen amino acids and is made by solid-phase peptide synthesis. Researchers study it for metabolic effects rather than for the growth-promoting actions associated with full human growth hormone. Its small size distinguishes it from the complete 191-amino-acid hormone.
Several names appear in scientific and commercial settings. AOD9604 and AOD-9604 are development codes used interchangeably, while hGH fragment 176-191 describes the same region. The peptide includes a disulfide bond between two cysteine residues, which helps shape its three-dimensional structure. Different suppliers may provide acetate or other salt forms, and purity can vary. These differences matter because analytical tests and biological assays can respond to the specific form being studied.
According to the manufacturer's website, the insulin's action profile in cats was similar to that of NPH insulin, and it lowered blood sugar quickly, but for only about 6–8 hours. Vetsulin was recalled in the US in November 2009 due to inconsistent strength; it was available again as of April 2013. Two ultra-slow time-release synthetic human insulins became available in 2004 and 2005, generically known as insulin detemir (Levemir) and insulin glargine (Lantus). Studies have had good results with insulin glargine in cats. Follow-up research shows that Levemir can be used with a similar protocol and that either insulin on this protocol can lead uncomplicated feline cases to remission, with the most success being in cats who start on these protocols as soon as possible after diagnosis.
The copper-catalysis of the Huisgen 1,3-dipolar cycloaddition was discovered concurrently and independently by the groups of Fokin and Sharpless and Meldal. The copper-catalyzed version of this reaction gives only the 1,4-isomer, whereas Huisgen's non-catalyzed 1,3-dipolar cycloaddition gives both the 1,4- and 1,5-isomers and requires a temperature of 100 °C.
Many bird species migrate to take advantage of global differences of seasonal temperatures, therefore optimising availability of food sources and breeding habitat. These migrations vary among the different groups. Many landbirds, shorebirds, and waterbirds undertake annual long-distance migrations, usually triggered by the length of daylight as well as weather conditions. These birds are characterised by a breeding season spent in the temperate or polar regions and a non-breeding season in the tropical regions or opposite hemisphere. Before migration, birds substantially increase body fats and reserves and reduce the size of some of their organs. Migration is highly demanding energetically, particularly as birds need to cross deserts and oceans without refuelling. Landbirds have a flight range of around 2,500 km (1,600 mi) and shorebirds can fly up to 4,000 km (2,500 mi), although the bar-tailed godwit is capable of non-stop flights of up to 10,200 km (6,300 mi). Some seabirds undertake long migrations, with the longest annual migrations including those of Arctic terns, which were recorded travelling an average of 70,900 km (44,100 mi) between their Arctic breeding grounds in Greenland and Iceland and their wintering grounds in Antarctica, with one bird covering 81,600 km (50,700 mi), and sooty shearwaters, which nest in New Zealand and Chile and make annual round trips of 64,000 km (39,800 mi) to their summer feeding grounds in the North Pacific off Japan, Alaska and California. Other seabirds disperse after breeding, travelling widely but having no set migration route.
=== Soft-matter and colloidal physics === Mezzenga's research focuses on the physics of self-assembly in polymers, surfactants, proteins, and biological colloids. A central theme of his work is the application of polymer and colloidal physics concepts to complex biological systems, particularly amyloid fibrils and other chiral filamentous materials such as nanocellulose. In 2010, Mezzenga and collaborators developed a statistical and theoretical framework for understanding amyloid fibril aggregation based on the analysis of atomic force microscopy images. This work introduced a polymer-physics-based methodology to study amyloid fibrils that has since been applied broadly to filamentous colloidal systems. In 2018, his group solved a long-standing conundrum in biological liquid crystals by discovering cholesteric phases in amyloid fibrils, which were previously known to form nematic phases but were thought to lack the chiral nematic form.
refractory 1. Having a high melting point. 2. A material that is resistant to decomposition by heat, pressure, or chemical attack, and retains its strength and form at high temperatures, making it suitable for applications in environments exposed to such conditions. Refractories are usually polycrystalline, polyphase, inorganic, non-metallic, porous, and heterogeneous compounds.
Sources: en.wikipedia.org
This fostered the amassing of enormous economic and political power by a few prominent industrialists, largely through the formation of trusts and monopolies to prevent competition. This resulted in significant increases in economic inequality, slum conditions, and civil unrest, creating a fertile environment for labor unions to flourish and, to a more limited extent, socialist movements to emerge. This period eventually ended with the advent of the Progressive Era, which was characterized by significant economic, legislative and social reforms. Pro-American elements in Hawaii overthrew the Hawaiian monarchy; the islands were annexed in 1898. That same year, Puerto Rico, the Philippines, and Guam were ceded to the U.S. by Spain after the latter's defeat in the Spanish–American War. (The Philippines was granted full independence from the U.S. on July 4, 1946, following World War II. Puerto Rico and Guam have remained U.S. territories.) American Samoa was acquired by the United States in 1900 after the Second Samoan Civil War. The U.S. Virgin Islands were purchased from Denmark in 1917 after Danish voters approved the sale in a 1916 referendum.
Health technology is defined by the World Health Organization as the "application of organized knowledge and skills in the form of devices, medicines, vaccines, procedures, and systems developed to solve a health problem and improve quality of lives". This includes pharmaceuticals, devices, procedures, and organizational systems used in the healthcare industry, as well as computer-supported information systems. In the United States, these technologies involve standardized physical objects, as well as traditional and designed social means and methods to treat or care for patients.
Opioid-induced hyperalgesia – where individuals using opioids to relieve pain paradoxically experience more pain as a result of that medication – has been observed in some people. This phenomenon, although uncommon, is seen in some people receiving palliative care, most often when dose is increased rapidly. If encountered, rotation between several different opioid pain medications may decrease the development of increased pain. Opioid induced hyperalgesia more commonly occurs with chronic use or brief high doses, but some research suggests that it may also occur with small doses. Side effects such as hyperalgesia and allodynia, sometimes accompanied by a worsening of neuropathic pain, may be consequences of long-term treatment with opioid analgesics, especially when increasing tolerance has resulted in loss of efficacy and consequent progressive dose escalation over time. This appears to largely be a result of actions of opioid drugs at targets other than the three classic opioid receptors, including the nociceptin receptor, sigma receptor and Toll-like receptor 4, and can be counteracted in animal models by antagonists at these targets such as J-113,397, BD-1047 or (+)-naloxone respectively. No drugs are currently approved specifically for counteracting opioid-induced hyperalgesia in humans and in severe cases the only solution may be to discontinue use of opioid analgesics and replace them with non-opioid analgesic drugs.
== Research == Deudimethyltryptamine is under development by Helus Pharma (formerly Cybin). It is under development for the treatment of generalized anxiety disorder, anxiety disorders, and depressive disorders. As of July 2026, deudimethyltryptamine is in phase 2 clinical trials for generalized anxiety disorder and phase 1 trials for anxiety disorders and depressive disorders. It was also under development for the treatment of substance-related disorders and other psychiatric disorders, but development for these indications was discontinued.
July 29 Trevor Milton, billionaire and founder of the Nikola electric truck startup, is indicted on three counts of fraud. Suni Lee wins a gold medal in the gymnastics all-around competition, making her the first Asian American to win a gold medal in gymnastics during the Olympics. COVID-19 vaccination: Vermont becomes the first U.S. state to vaccinate 70% of children aged 12 to 17 years old. July 30 The Senate votes 66–28 to allow debates to begin on the Infrastructure Investment and Jobs Act. Tax returns of Donald Trump: The Department of Justice rules that the U.S. Treasury must hand the tax returns of former President Donald Trump to Congress. Swimming at the 2020 Summer Olympics: Caeleb Dressel breaks a world record in the 100m butterfly during the Olympics, finishing in 49.45 seconds. July 31 Florida swimmer Bobby Finke wins a gold medal at the 1500 metre freestyle event at the Olympics, becoming the first American to do so since Mike O'Brien. COVID-19 pandemic: Florida reports 21,683 cases of COVID-19, a new single-day record.
Sources: en.wikipedia.org
=== Genetic labeling === Fluorescence in situ hybridization (FISH), is an example of a genetic labeling technique that utilizes probes that are specific for chromosomal sites along the length of a chromosome, also known as chromosome painting. Multiple fluorescent dyes that each have a distinct excitation and emission wavelength are bound to a probe which is then hybridized to chromosomes. A fluorescence microscope can detect the dyes present and send it to a computer that can reveal the karyotype of a cell. This technique allows abnormalities such as deletions and duplications to be revealed.
During the Allied occupation of Germany after World War II, internal borders were redrawn by the Allied military governments. New states were established in all four zones of occupation: Bremen, Hesse, Württemberg-Baden, and Bavaria in the American zone; Hamburg, Schleswig-Holstein, Lower Saxony, and North Rhine-Westphalia in the British zone; Rhineland-Palatinate, Baden, Württemberg-Hohenzollern and the Saarland – which later received a special status – in the French zone; Mecklenburg(-Vorpommern), Brandenburg, Saxony, Saxony-Anhalt, and Thuringia in the Soviet zone. No single state comprised more than 30% of either population or territory; this was intended to prevent any one state from being as dominant within Germany as Prussia had been in the past. Initially, only seven of the pre-War states remained: Baden (in part), Bavaria (reduced in size), Bremen, Hamburg, Hesse (enlarged), Saxony, and Thuringia. The states with hyphenated names, such as Rhineland-Palatinate, North Rhine-Westphalia, and Saxony-Anhalt, owed their existence to the occupation powers and were created out of mergers of former Prussian provinces and smaller states. Former German territory that lay east of the Oder-Neisse line fell under either Polish or Soviet administration but attempts were made at least symbolically not to abandon sovereignty well into the 1960s.
It is now generally acknowledged that by itself, the low protein theory does not adequately account for the pathogenesis of kwashiorkor. More complex deficiencies are at work. These have still not been established. Social factors are also relevant and ignorance of nutrition can be a cause. A case was described where parents who fed their child cassava failed to recognize malnutrition because of the edema caused by the syndrome and thought the child was well-nourished despite the development of kwashiorkor.
In bacterial cells, ribosomes are synthesized in the cytoplasm through the transcription of multiple ribosome gene operons. In eukaryotes, the process takes place both in the cell cytoplasm and in the nucleolus, which is a region within the cell nucleus. The assembly process involves the coordinated function of over 200 proteins in the synthesis and processing of the four rRNAs, as well as assembly of those rRNAs with the ribosomal proteins.
=== Reproduction and development === Sows usually produce their first litter at the age of 3 to 5 years, with those living in more developed areas tending to get pregnant at younger ages. The breeding period usually occurs in the June–July period, though it can extend to August in the species' northern range. The breeding period lasts for two to three months. Both sexes are promiscuous. Males try to mate with several females, but large, dominant ones may violently claim a female if another mature male comes near. Copulation can last 20–30 minutes. Sows tend to be short-tempered with their mates after copulating. The fertilized eggs undergo delayed development and do not implant in the female's womb until November. The gestation period lasts 235 days, and litters are usually born in late January to early February. Litter size is between one and six cubs, typically two or three. At birth, cubs weigh 280–450 g (0.62–0.99 lb) and measure 20.5 cm (8.1 in) in length. They are born with fine, gray, down-like hair and their hind quarters are underdeveloped. They typically open their eyes after 28–40 days and begin walking after 5 weeks. Cubs are dependent on their mother's milk for 30 weeks and will reach independence at 16–18 months. At 6 weeks, they attain 900 g (2.0 lb), by 8 weeks they reach 2.5 kg (5.5 lb) and by 6 months they weigh 18 to 27 kg (40 to 60 lb). They reach sexual maturity at 3 years and attain their full growth at 5 years.
Sources: en.wikipedia.org
No, it is a synthetic peptide fragment corresponding to a small portion of hGH. It is not the full 191-amino-acid hormone and does not reproduce all of hGH's effects.
It is commonly described as a 16-amino-acid peptide based on residues 176-191 of human growth hormone. Some sources vary in notation, so checking the stated sequence is useful.
It is not typically described as a standalone natural hormone. The sequence is derived from the C-terminal region of human growth hormone, but the synthetic peptide is a laboratory-made construct.
Yes, the World Anti-Doping Agency classifies AOD-9604 as a prohibited peptide hormone and related substance. Its use by athletes is banned under the relevant anti-doping code.